{"id":12506,"date":"2026-02-19T05:47:11","date_gmt":"2026-02-19T05:47:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/12506\/"},"modified":"2026-02-19T05:47:11","modified_gmt":"2026-02-19T05:47:11","slug":"basilea-pharmaceutica-ltd-bpmuf-full-year-2025-earnings-call-highlights-strong-revenue","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/12506\/","title":{"rendered":"Basilea Pharmaceutica Ltd (BPMUF) Full Year 2025 Earnings Call Highlights: Strong Revenue …"},"content":{"rendered":"\n

This article first appeared on GuruFocus<\/a>.<\/p>\n

Total Revenue: CHF232.4 million, up 11.4% year-on-year.<\/p>\n

Cresemba Global In-Market Sales: USD693 million, a 27% increase year-on-year.<\/p>\n

Royalty Income: CHF111.6 million, a 15.4% increase year-on-year.<\/p>\n

Operating Profit: CHF51.5 million.<\/p>\n

Net Profit: CHF40.2 million.<\/p>\n

Cash and Cash Equivalents: CHF162.3 million, a 30% increase.<\/p>\n

Net Cash Position: CHF86.9 million, tripling from the end of 2024.<\/p>\n

Operating Cash Flow: CHF62.1 million.<\/p>\n

Convertible Debt: Reduced to CHF76 million.<\/p>\n

R&D Expenses: Operating expenses at CHF141.5 million, reflecting increased R&D investments.<\/p>\n

Milestone and Upfront Payments: CHF32 million.<\/p>\n

Cost of Products Sold: CHF39.3 million.<\/p>\n

Release Date: February 17, 2026<\/p>\n

For the complete transcript of the earnings call, please refer to the full earnings call transcript<\/a>.<\/p>\n

Cresemba’s global in-market sales increased by 27% to USD693 million, demonstrating strong demand and market leadership.<\/p>\n

Zevtera was successfully launched in the US, with expectations for increased commercial uptake starting in the second quarter of 2026.<\/p>\n

Basilea Pharmaceutica Ltd (BPMUF<\/a>) achieved a robust financial performance, with total revenue increasing by 11% to CHF232 million.<\/p>\n

The company significantly reduced its convertible debt to CHF76 million and tripled its net cash position.<\/p>\n

Basilea expanded its pipeline by in-licensing the Phase 3-ready asset ceftibuten-ledaborbactam, targeting a new market for complicated urinary tract infections.<\/p>\n

The anticipated loss of exclusivity for Cresemba in the US and Europe could impact revenues starting in 2027 and 2028, respectively.<\/p>\n

Increased research and development expenses are expected to rise by approximately 20% in 2026, reflecting higher investments in ongoing studies.<\/p>\n

The company faces potential challenges with the entry of generics for Cresemba, which could affect market share and revenue.<\/p>\n

Product revenue is expected to decrease due to reduced product supply to partners Pfizer and Gosun as they transition to manufacturing their own supply.<\/p>\n

The timeline for the Phase 3 program of ceftibuten-ledaborbactam is extended, with the study expected to start in early 2027 and readout in 2029.<\/p>\n

Q: Regarding Cresemba’s loss of exclusivity, is there any ongoing litigation that might affect the timing of generic entry in the US? Also, why has there been a focus on in-licensing antibacterial assets recently? A: David Veitch, CEO: We are not directly involved in any litigation as we are not the Marketing Authorization Holder in the US. Generics will not be approved until the loss of exclusivity date, and we expect only a handful of generics to enter the market. Adesh Kaul, CFO: The focus on antibacterial assets is due to the availability of assets and the ongoing medical need in that space. There are fewer antifungal assets available for partnering.<\/p>\n

Story Continues <\/p>\n

Q: Can you clarify the CHF600 million cumulative cash flow from Cresemba and Zevtera between 2026 and 2030? Is this based on gross profit? A: Adesh Kaul, CFO: Yes, the CHF600 million cumulative cash flow is based on gross profit. For 2026, we expect CHF200 million in revenue from these assets, with a cash contribution of CHF170 million after deducting the cost of goods sold.<\/p>\n

Q: What are the expectations for peak annual sales of Zevtera in the US, and how large is the market opportunity for Cresemba in Japan? A: David Veitch, CEO: Analysts estimate peak US sales for Zevtera to be between CHF200 million and CHF300 million. In Japan, Cresemba is growing rapidly, with sales already exceeding expectations. The market opportunity is significant, with Japan showing a growth rate of 220%.<\/p>\n

Q: When do you expect to complete enrollment for the fosmanogepix and ceftibuten-ledaborbactam Phase 3 programs? A: Marc Engelhardt, CMO: We anticipate completing enrollment for the fosmanogepix Phase 3 studies in the second half of 2027, with a readout in early 2028. The ceftibuten-ledaborbactam program is expected to follow approximately 9 to 12 months later.<\/p>\n

Q: What is the development strategy for BAL2062, and how do you plan to address azole-resistant invasive aspergillosis? A: Marc Engelhardt, CMO: Our strategy is to develop BAL2062 for a broader indication of invasive aspergillosis, not solely focusing on resistant populations. The drug’s efficacy and safety profile support its use as a first-line treatment, although it will also be effective against resistant strains.<\/p>\n

For the complete transcript of the earnings call, please refer to the full earnings call transcript<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"This article first appeared on GuruFocus. Total Revenue: CHF232.4 million, up 11.4% year-on-year. Cresemba Global In-Market Sales: USD693…\n","protected":false},"author":2,"featured_media":12507,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[77,9165,9167,8738,9166,9164,7136],"class_list":{"0":"post-12506","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-basel","8":"tag-basel","9":"tag-cash-and-cash-equivalents","10":"tag-cash-position","11":"tag-cresemba","12":"tag-david-veitch","13":"tag-operating-cash-flow","14":"tag-operating-profit"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/12506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=12506"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/12506\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/12507"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=12506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=12506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=12506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}